Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy
KCT0006908Phase 3Not yet recruiting
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ferric carboxymaltose in gastric cancer (GC) and iron deficiency anemia (IDA) (2 arms), sponsored by JW Pharmaceutical Corporation. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
gastric cancer (GC)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on KCT0006908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006908.